Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP)

Tracy A. Brennan, Carter M. Lindborg, Christian R. Bergbauer, Haitao Wang, Frederick S. Kaplan, Robert Pignolo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Episodic flare-ups of fibrodysplasia ossificans progressiva (FOP) are characterized clinically by severe, often posttraumatic, connective tissue swelling and intramuscular edema, followed histologically by an intense and highly angiogenic fibroproliferative reaction. This early inflammatory and angiogenic fibroproliferative response is accompanied by the presence of abundant mast cells far in excess of other reported myopathies. Results: Using an injury-induced, constitutively-active transgenic mouse model of FOP we show that mast cell inhibition by cromolyn, but not aprepitant, results in a dramatic reduction of heterotopic ossification. Cromolyn, but not aprepitant, significantly decreases the total number of mast cells in FOP lesions. Furthermore, cromolyn specifically diminishes the number of degranulating and resting degranulated mast cells in pre-osseous lesions. Conclusions: This work demonstrates that consideration of FOP as a type of localized mastocytosis may offer new therapeutic interventions for treatment of this devastating condition.

Original languageEnglish (US)
Pages (from-to)259-266
Number of pages8
JournalBone
Volume109
DOIs
StatePublished - Apr 1 2018

Fingerprint

Myositis Ossificans
aprepitant
Mast Cells
Cromolyn Sodium
Mastocytosis
Heterotopic Ossification
Muscular Diseases
Therapeutics
Connective Tissue
Transgenic Mice
Edema
Wounds and Injuries

Keywords

  • ACVR1
  • Cromolyn
  • Fibrodyplasia ossificans progressiva (FOP)
  • Heterotopic ossification
  • Mast cells

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Histology

Cite this

Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP). / Brennan, Tracy A.; Lindborg, Carter M.; Bergbauer, Christian R.; Wang, Haitao; Kaplan, Frederick S.; Pignolo, Robert.

In: Bone, Vol. 109, 01.04.2018, p. 259-266.

Research output: Contribution to journalArticle

Brennan, Tracy A. ; Lindborg, Carter M. ; Bergbauer, Christian R. ; Wang, Haitao ; Kaplan, Frederick S. ; Pignolo, Robert. / Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP). In: Bone. 2018 ; Vol. 109. pp. 259-266.
@article{57387ee7c7654796a686e1ed7a911fc2,
title = "Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP)",
abstract = "Background: Episodic flare-ups of fibrodysplasia ossificans progressiva (FOP) are characterized clinically by severe, often posttraumatic, connective tissue swelling and intramuscular edema, followed histologically by an intense and highly angiogenic fibroproliferative reaction. This early inflammatory and angiogenic fibroproliferative response is accompanied by the presence of abundant mast cells far in excess of other reported myopathies. Results: Using an injury-induced, constitutively-active transgenic mouse model of FOP we show that mast cell inhibition by cromolyn, but not aprepitant, results in a dramatic reduction of heterotopic ossification. Cromolyn, but not aprepitant, significantly decreases the total number of mast cells in FOP lesions. Furthermore, cromolyn specifically diminishes the number of degranulating and resting degranulated mast cells in pre-osseous lesions. Conclusions: This work demonstrates that consideration of FOP as a type of localized mastocytosis may offer new therapeutic interventions for treatment of this devastating condition.",
keywords = "ACVR1, Cromolyn, Fibrodyplasia ossificans progressiva (FOP), Heterotopic ossification, Mast cells",
author = "Brennan, {Tracy A.} and Lindborg, {Carter M.} and Bergbauer, {Christian R.} and Haitao Wang and Kaplan, {Frederick S.} and Robert Pignolo",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.bone.2017.08.023",
language = "English (US)",
volume = "109",
pages = "259--266",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP)

AU - Brennan, Tracy A.

AU - Lindborg, Carter M.

AU - Bergbauer, Christian R.

AU - Wang, Haitao

AU - Kaplan, Frederick S.

AU - Pignolo, Robert

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: Episodic flare-ups of fibrodysplasia ossificans progressiva (FOP) are characterized clinically by severe, often posttraumatic, connective tissue swelling and intramuscular edema, followed histologically by an intense and highly angiogenic fibroproliferative reaction. This early inflammatory and angiogenic fibroproliferative response is accompanied by the presence of abundant mast cells far in excess of other reported myopathies. Results: Using an injury-induced, constitutively-active transgenic mouse model of FOP we show that mast cell inhibition by cromolyn, but not aprepitant, results in a dramatic reduction of heterotopic ossification. Cromolyn, but not aprepitant, significantly decreases the total number of mast cells in FOP lesions. Furthermore, cromolyn specifically diminishes the number of degranulating and resting degranulated mast cells in pre-osseous lesions. Conclusions: This work demonstrates that consideration of FOP as a type of localized mastocytosis may offer new therapeutic interventions for treatment of this devastating condition.

AB - Background: Episodic flare-ups of fibrodysplasia ossificans progressiva (FOP) are characterized clinically by severe, often posttraumatic, connective tissue swelling and intramuscular edema, followed histologically by an intense and highly angiogenic fibroproliferative reaction. This early inflammatory and angiogenic fibroproliferative response is accompanied by the presence of abundant mast cells far in excess of other reported myopathies. Results: Using an injury-induced, constitutively-active transgenic mouse model of FOP we show that mast cell inhibition by cromolyn, but not aprepitant, results in a dramatic reduction of heterotopic ossification. Cromolyn, but not aprepitant, significantly decreases the total number of mast cells in FOP lesions. Furthermore, cromolyn specifically diminishes the number of degranulating and resting degranulated mast cells in pre-osseous lesions. Conclusions: This work demonstrates that consideration of FOP as a type of localized mastocytosis may offer new therapeutic interventions for treatment of this devastating condition.

KW - ACVR1

KW - Cromolyn

KW - Fibrodyplasia ossificans progressiva (FOP)

KW - Heterotopic ossification

KW - Mast cells

UR - http://www.scopus.com/inward/record.url?scp=85028617467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028617467&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2017.08.023

DO - 10.1016/j.bone.2017.08.023

M3 - Article

C2 - 28851540

AN - SCOPUS:85028617467

VL - 109

SP - 259

EP - 266

JO - Bone

JF - Bone

SN - 8756-3282

ER -